Compare InMode Ltd (INMD) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
InMode Ltd vs Smith & Nephew plc — how do they compare? InMode Ltd trades at $14.21 (market cap $809.93M), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 13.7× InMode Ltd's market cap, and Smith & Nephew plc pays a 2.95% dividend while InMode Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold InMode Ltd for 28 Days and Smith & Nephew plc for 121 Days on average.
| INMD | SNN | |
|---|---|---|
Market Cap | $809.93M | $11.10B |
Volume | 365,490 | 1,051,703 |
Sector | Health | Health |
52-Week High | $16.62 | $37.17 |
52-Week Low | $12.76 | $26.42 |
Typical Hold Time | 28 Days | 121 Days |
Enterprise Value | $313.27M | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
InMode (INMD) trades at $14.21, up 1.43% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with a P/E of 11.63, gross margins of 76.52%, and consistent profitability. Recent Q2 2026 earnings beat expectations with $95.6M revenue, while facing shareholder activism from Steel Partners' $16.75 per share acquisition offer.
Investment outlook remains cautious with analyst consensus divided (45% Buy, 55% Hold) amid cyclical industry softness. Key opportunities include international growth and new product launches like Morpheus8 Cool, while risks involve US sales declines and capital allocation concerns. The stock presents value characteristics but requires monitoring of management's strategic response to acquisition pressure.
Smith+Nephew (SNN) trades at $27.24, near its 52-week low of $27.05, with a bearish technical signal despite recent earnings beats. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%, but the stock faces headwinds from analyst downgrades and CFO departure news. Product launches like the EVOS PELVIC System highlight innovation, yet investor sentiment remains cautious.
The outlook is mixed: strong fundamentals and undervaluation (P/E 18.34) offer upside, but technical weakness and competitive risks temper near-term gains. Key risks include execution challenges and market volatility, while institutional interest (e.g., BlackRock's $505M stake) provides support. Investors should weigh solid profitability against sentiment-driven price pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
